Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK‐positive non‐small‐cell lung cancer: Case report and review of the literature

Abstract

Abstract Non‐small cell lung cancer patients with anaplastic lymphoma kinase or c‐ros oncogene 1 mutations who are treated with the tyrosine kinase inhibitor crizotinib rarely develop crizotinib‐associated renal cysts (CARCs). Here, we present a case report and review of the literature supporting the hypothesis that CARCs may correlate positively with progression‐free survival.

Keywords

• ALK positive
• crizotinib
• non‐small‐cell lung cancer
• progression‐free survival
• renal cysts